Allot’s analyst price targets currently span from US$11 to US$19, while the model fair value sits at US$13.38 per share, so you are looking at a fairly tight but divided range of outcomes. The higher ...
Pankaj Belwariar, Director Communications, SRM University-AP, writes on forces reshaping search, decline of traditional ...
Maze Therapeutics (MAZE), a clinical stage biopharmaceutical company focused on renal, cardiovascular and metabolic diseases, has recently drawn attention as investors consider its pipeline progress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results